Home Global Market Samsung Biologics receives 2022 CMO Leadership Award in all six categories

Samsung Biologics receives 2022 CMO Leadership Award in all six categories

by admin
0 comment
Samsung Biologics

Summary :

Samsung Biologics, the world’s leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science Leader. Samsung Biologics received a total of six CMO Leadership Awards across all performance categories: capabilities, compatibility, expertise, reliability, quality, and service.

Now in its 11th year, the CMO Leadership Awards offer accurate and reliable customer feedback to provide support in choosing a reputable partner for development and manufacturing needs within the biopharmaceutical and pharmaceutical industry. Since 2013, Samsung Biologics has been recognized in the CMO Leadership Awards for nine consecutive years.

Samsung Biologics

“We are incredibly proud to receive this distinction across all six performance categories, especially at this pivotal moment in healthcare when it is more crucial than ever to successfully supply medicines to our clients and save the lives of patients,” said John Rim, President and CEO of Samsung Biologics. “This recognition reminds us of our responsibility as a trusted CDMO partner to our clients and to respond quickly to the evolving needs in the industry.”

“For nearly a decade, these awards have proven most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities,” said Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma. “Our research arm, Industry Standard Research (ISR), which only surveys drug sponsors who have worked recently with specific CDMOs, ensures the validity of these results. Our winners will be your champions of outsourcing.”

Samsung Biologics demonstrated strong operational performance and business agility in 2021 with all Plants 1, 2, and 3 in stable operations. Plant 4 will commence partial operations in Q4 this year with full completion expected mid-next year, and the company will also begin construction of Plant 5 within 2022 where it will offer multi-modal product services in addition to the mRNA vaccine drug substance (DS) manufacturing suite expected to be ready for cGMP operations within the earlier part of this year.

About Samsung Biologics

Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing services to the biopharmaceutical industry. Samsung BioLogics is a CMO that produces biopharmaceutical products for established brands such as Bristol-Myers Squibb and Roche. The company was founded by Samsung Electronics, Samsung Everland, Samsung C&T and Quintiles Transnational.

Company Description: SAMSUNG BIOLOGICS Co., Ltd. is located in Incheon, Incheon, Republic Of Korea and is part of the Pharmaceutical and Medicine Manufacturing Industry.
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

ChemRobotics is a global Scientific, Technical & Business data intelligence company, especially in the field of Pharmaceutical, Agrochemical, Veterinary and Fine Chemical.

ChemRobotics Times

Subscribe ChemRobotics for the latest updates in the Pharmaceutical, Agrochemical, Veterinary, and Fine Chemical Industries

Laest News

ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved. 

Designed and Developed by Ample eBusiness